Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
NCT05279859 · Erasca, Inc. · PHASE1/PHASE2 · withdrawn · last registry update 2022-06-15 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision.” | Open Targets' class: business administrative | Registry record, Erasca, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FLT3 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-10-05Results posted on the registry: Daiichi Sankyo, Chemotherapy + Quizartinib (NCT02668653)
- 2022-06-27Results posted on the registry: Astellas Pharma Global Development, Inc., Gilteritinib + Placebo (NCT02927262)
- 2022-06-24Results posted on the registry: Astellas Pharma Global Development, Inc., gilteritinib + atezolizumab (NCT03730012)
- 2022-01-05Phase 3 first posted: Chen Suning, Venetoclax + Decitabine for Injection (NCT05177731)
- 2021-08-19Results posted on the registry: Daiichi Sankyo Co., Ltd., Quizartinib + Cytarabine (NCT02834390)
- 2021-08-16Results posted on the registry: Astellas Pharma Global Development, Inc., Gilteritinib (NCT02561455)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision